Andrx Asks FDA To Reconsider Petition To Block Biovail Diltiazem ER Generic
Executive Summary
Andrx is petitioning FDA to reconsider its denial of the firm's previous citizen's petition in an effort to prevent market entry of Biovail's generic version of Hoechst Marion Roussel's Cardizem CD after expiration of Andrx' exclusivity Dec. 19.